ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Multifunctional Bioactive Scaffold Facilitating BMSCs-Driven Osteogenesis and Vascularization in Critical-Sized Bone Defect Repair.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- FGFR1 signaling in rheumatoid arthritis: Mechanisms of bone destruction and therapeutic targeting (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Critical-sized bone defects (CSD) remain a major clinical challenge due to three interrelated barriers: inadequate mechanical support, insufficient osteogenic induction, and impaired angiogenesis, all of which hinder effective regeneration. To tackle these, we developed a dual-network bioactive scaffold, ermd bFGF@CB-gel, based on a chondroitin sulfate methacryloyl/bacterial cellulose gel (CB-gel) which synergistically combines three key properties: i) a photocurable biomimetic mineralized scaffold (CB-gel) for in situ bone repair with mechanical support and a bone-ECM-mimicking microenvironment for delivering bone marrow mesenchymal stem cells (BMSCs); ii) a bio-nano carrier (BC) for sustained release of bFGF which enhances the adhesion and proliferation via EGFL/Itga2b pathway, strengthens osteogenic differentiation and mineralization by activating the COMP/PI3K/AKT pathway of rat BMSCs; iii) bFGF released by the dual-network promotes migration and angiogenesis of microvascular endothelial cells by combining FGFR to activate the PI3K/AKT/eNOS pathway. In a rat CSD model, the bFGF@CB-gel achieved a statistically significant increase in new bone volume, as quantified by micro-CT, and enhanced vascular density, evaluated via immunohistochemical staining. These findings highlight the potential of bFGF@CB-gel as an effective local delivery system of BMSCs via linking biomechanics, molecular signaling, and cellular activity, which moves beyond simplistic function stacking to a rational, synergistic design for bone regeneration in CSD, addressing key challenges in reconstructive surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.